Citations

Clear

1053 citation(s) found for "Andre, F".

Real world outcomes of bispecific T-cell engagers in plasma cell leukemia
Gaballa, Mahmoud, Julian, Kelley, Afrough, Aimaz, Hansen, Doris, Goel, Utkarsh, Corraes, Andre De Menezes Silva, Dima, Danai, Rana, Masooma, Hosoya, Hitomi, Mikkilineni, Lekha, Fogel, Lindsay, Raza, Shahzad, Banerjee, Rahul, Zanwar, Saurabh, Pasvolsky, Oren, Sannareddy, Aishwarya, Borogovac, Azra, Davis, James, Green, Kimberly, Biran, Noa, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Atrash, Shebli, Ferreri, Christopher, Richards, Tiffany, Abid, Muhammad Bilal, Bal, Susan, Ali, Hossam M., Ye, J Christine, Richard, Shambavi, Kaur, Gurbakhash, Shain, Kenneth, Puglianini, Omar Alexis Castaneda, Rossi, Adriana, Anderson, Larry, Voorhees, Peter, Khouri, Jack, Sidana, Surbhi, Portuguese, Andrew, Janakiram, Murali, Lee, Hans, Lin, Yi, Grajales-Cruz, Ariel, Patel, Krina, Sborov, Douglas, Sidana, Surbhi , Hosoya, Hitomi , Davis, James A. , Ali, Hossam M. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Ali, Hossam M , Sannareddy, Aishwarya , Gaballa, Mahmoud, Julian, Kelley, Afrough, Aimaz, Hansen, Doris, Goel, Utkarsh, Corraes, Andre De Menezes Silva, Dima, Danai, Rana, Masooma, Mikkilineni, Lekha, Fogel, Lindsay, Raza, Shahzad, Banerjee, Rahul, Zanwar, Saurabh, Pasvolsky, Oren, Borogovac, Azra, Davis, James, Green, Kimberly, Biran, Noa, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Atrash, Shebli, Ferreri, Christopher, Richards, Tiffany, Abid, Muhammad Bilal, Bal, Susan, Ali, Hossam M., Ye, J Christine, Richard, Shambavi, Kaur, Gurbakhash, Shain, Kenneth, Puglianini, Omar Alexis Castaneda, Rossi, Adriana, Anderson, Larry, Voorhees, Peter, Khouri, Jack, Portuguese, Andrew, Janakiram, Murali, Lee, Hans, Lin, Yi, Grajales-Cruz, Ariel, Patel, Krina, Sborov, Douglas

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 823-823

10.1182/blood-2025-823 Get It

Abstract Background Patients (pts) with plasma cell leukemia (PCL) were excluded from key trials, so we assessed their outcomes with standard of care bispecific antibodies (BsAbs). Methods Our multicenter retrospective US Myeloma consortium study included PCL pts treated with BsAbs. PCL was defined as ≥5% circulating plasma cells, including primary PCL, secondary PCL, historical PCL, and active PCL within 30 days of BsAb initiation. Endpoints were toxicity rates, overall response (ORR), progression-free survival (PFS), and overall survival (OS). Results Our study involved 122 PCL pts from 15 US centers with: 27% primary PCL, 65% secondary PCL, 51% active PCL, 53% women, median age of 65 years (range 31-83), 77% white, 15% black, 60% high-risk cytogenetics, 45% high bone marrow burden (≥50% plasma cells), 5% CNS myelomatosis, and 20% EMD. Median prior lines of therapy (tx) were 6 (IQR 5-9), 94% triple-refractory, 57% penta-refractory, 73% prior transplant, and 57% prior BCMA tx (70% in talquetamab group, 41% in BCMA BsAb group). Treatments included 4 cohorts: 37% teclistamab, 11% elranatamab, 42% talquetamab definitive tx, and 11% talquetamab bridge to CAR-T. BsAb was used either as monotherapy (94%) or in combination (6%) with other agents. CRS grade (G) 1 was 41%, G2 14.8%, G3 2.5%, and G4 1.6%, while ICANS G1 was 8.2%, G2 7.4%, G3 3.3%, and G4 1.6%. Infections occurred in 34% and median hospitalization was 10 days (IQR 8-15). Of 110 evaluable pts, ORR was 54.5%, with 24.5% CR, 13.6% VGPR, and 16.4% PR. The ORR was 60.8% for talquetamab definitive tx (21.6% CR, 23.5% VGPR, 15.7% PR), 46.2% for elranatamab (38.5% CR, 7.7% PR), and 33.3% for teclistamab (20% CR, 4.4% VGPR, 8.9% PR). Talquetamab bridge to CAR-T in 12 evaluable pts had a pre-CAR-T day 30 ORR of 58.3% (16.7% CR, 8.3% VGPR, 33.3% PR). With a median follow-up of 8.3 months (mo), the median (m) PFS was 3.2 mo, and mOS was 9.2 mo, with similar outcomes between primary vs. secondary PCL (p=0.37 for PFS, p=0.18 for OS). Talquetamab definitive tx had better outcomes with a mPFS of 5.5 mo, mOS of 11.5 mo, 10-mo PFS of 31.2%, and 10-mo OS of 55.7%, and further improved when used as a bridge to CAR-T, with unreached mPFS, unreached mOS, 10-mo PFS of 53.8%, and 10-mo OS of 62.7%. BCMA BsAbs had inferior outcomes, with teclistamab yielding a mPFS of 1.2 mo, mOS of 8.1 mo, 10-mo PFS of 15.3%, and 10-mo OS of 44.3%, while elranatamab showed a mPFS of 1.6 mo and mOS of 3.6 mo (p=0.007 for PFS, p=0.023 for OS). In BCMA naive pts, BCMA BsAbs' outcomes remained inferior to talquetamab with a mPFS of 1.2 mo and mOS of 3.4 mo (p=0.003, 0.001). Sixty pts with active PCL had a poor mPFS (1.6 vs. 4.4 mo, p=0.036) and mOS (5.3 vs. 10.7 mo, p=0.004) compared to pts with only historical PCL. However, in active PCL, talquetamab definitive tx (n=29) showed superior outcomes with a mPFS of 6.9 mo and mOS of 12.2 mo (p=0.003, 0.012). Talquetamab bridge to CAR-T (n=3) showed a mPFS of 3.2 mo and mOS of 5.2 mo. BCMA BsAbs had inferior outcomes: teclistamab with a mPFS of 0.7 mo and mOS of 1.4 mo, while elranatamab showed a mPFS of 1.0 mo and mOS of 3.1 mo (p=0.003, 0.012). In BCMA naive pts, BCMA BsAbs' efficacy remained poor with a mPFS of 0.7 mo and mOS of 1.4 mo (p=0.006, 0.002). While in pts with only historical PCL (without active PCL), BCMA BsAbs in BCMA naive pts led to similar outcomes with a mPFS of 5.2 mo and mOS of 8.5 mo, compared to a mPFS of 3.7 mo and mOS of 10.4 mo with talquetamab (p=0.90, 0.86). Multivariable analysis (MVA) associated active PCL with worse PFS (p=0.035, HR=1.93, CI 1.05-3.55) and OS (p=0.017, HR=2.3, CI 1.16-4.60), talquetamab with improved PFS (p=0.009, HR=0.41, CI 0.21-0.81) and OS (p=0.012, HR=0.40, CI 0.19-0.82), and talquetamab bridge to CAR-T with improved PFS (p=0.042, HR 0.28, CI 0.08-0.95) without reaching statistical significance for OS (p=0.11, HR 0.29, HR 0.07-1.3). MVA results remained similar when the talquetamab bridge to CAR-T cohort was excluded. Conclusions Despite PCL's poor prognosis, talquetamab was superior to BCMA BsAbs in active PCL, with a mPFS of 6.9 mo and mOS of 12.2 mo, aligning with the broader cohort. BCMA BsAbs had poor efficacy in active PCL, even in BCMA naive pts, with a mPFS of 0.7 mo and mOS of 1.4 mo. In historical PCL without active PCL, BCMA BsAbs in BCMA-naive pts showed comparable outcomes to talquetamab. In the overall cohort, talquetamab bridge to CAR-T improved PFS without reaching significance for OS benefit in MVA.
Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas
Afrough, Aimaz, Pasvolsky, Oren, Zanwar, Saurabh, Gaballa, Mahmoud, Sannareddy, Aishwarya, Dima, Danai, Goel, Utkarsh, Ali, Hossam M., Julian, Kelley, Corraes, Andre, Cassano, Raffaella, Janakiram, Murali, Goldsmith, Scott, Davis, James, Green, Kimberly, Biran, Noa, Fogel, Lindsay, Zolotov, Eli, Herr, Megan, Hassan, Hamza, Shune, Leyla, Kort, Jeries, Bal, Susan, Costa, Luciano, Ye, J Christine, Joiner, Laura, Raza, Shahzad, Anwer, Faiz, Khouri, Jack, Banerjee, Rahul, Portuguese, Andrew, Sidana, Surbhi, Rana, Masooma, Mikkilineni, Lekha, Hosoya, Hitomi, Atrash, Shebli, Ferreri, Christopher, Varga, Cindy, Sborov, Douglas, Midha, Shonali, Nadeem, Omar, Grajales-Cruz, Ariel, Baz, Rachid, Blue, Brandon, Freeman, Ciara Louise, Locke, Frederick, Patel, Krina, Lin, Yi, Kumar, Shaji, Hansen, Doris, Anderson, Larry, Voorhees, Peter, Puglianini, Omar Alexis Castaneda, Sidana, Surbhi , Hosoya, Hitomi , Davis, James A. , Ali, Hossam M. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Ali, Hossam M , Sannareddy, Aishwarya , Afrough, Aimaz, Pasvolsky, Oren, Zanwar, Saurabh, Gaballa, Mahmoud, Dima, Danai, Goel, Utkarsh, Ali, Hossam M., Julian, Kelley, Corraes, Andre, Cassano, Raffaella, Janakiram, Murali, Goldsmith, Scott, Davis, James, Green, Kimberly, Biran, Noa, Fogel, Lindsay, Zolotov, Eli, Herr, Megan, Hassan, Hamza, Shune, Leyla, Kort, Jeries, Bal, Susan, Costa, Luciano, Ye, J Christine, Joiner, Laura, Raza, Shahzad, Anwer, Faiz, Khouri, Jack, Banerjee, Rahul, Portuguese, Andrew, Rana, Masooma, Mikkilineni, Lekha, Atrash, Shebli, Ferreri, Christopher, Varga, Cindy, Sborov, Douglas, Midha, Shonali, Nadeem, Omar, Grajales-Cruz, Ariel, Baz, Rachid, Blue, Brandon, Freeman, Ciara Louise, Locke, Frederick, Patel, Krina, Lin, Yi, Kumar, Shaji, Hansen, Doris, Anderson, Larry, Voorhees, Peter, Puglianini, Omar Alexis Castaneda

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 825-825

10.1182/blood-2025-825 Get It

Abstract Background: Talquetamab (Talq), a GPRC5D-targeting bispecific antibody, shows promising activity in relapsed/refractory multiple myeloma (RRMM). However, outcomes in patients (pts) with soft tissue plasmacytoma (STP) remain poorly characterized. Method: We retrospectively analyzed 463 RRMM pts treated with Talq at 15 U.S. centers by Dec 2024. Pts were grouped by presence of STP at Talq start: (1) extramedullary disease (EMD; lesions not contiguous with bone), (2) paraskeletal disease (PSK; bone-contiguous), (3) EMD + PSK, and (4) No-STP. Those receiving Talq as a bridge-to-CAR T (n=103, 22%) were censored at CAR T infusion if progression had not occurred. Time-to-event endpoints were calculated from Talq step-up, using Kaplan-Meier/Cox models. Result: Median age was 66 years (y) (35–89); 54 (11.7%) had EMD, 26 (5.6%) PSK, 60 (13%) EMD+PSK, and 320 (69%) No-STP. EMD pts were younger than No-STP (62 vs 66 y, p=.009), while PSK (66.5) and EMD+PSK (64.5) were similar to No-STP. Median prior lines were higher in PSK (7) vs EMD (5), EMD+PSK (6) and No-STP (6) (p=.035). Median time from diagnosis to Talq was shortest in EMD (3.8 y), followed by EMD+PSK (4.6 y), vs PSK (6.4 y), and No-STP (5.9 y) (p=.015). Among pts with any EMD (EMD or EMD+PSK), 81 (69%) had visceral involvement and 85 (73%) had multiple lesions. Rates of prior BCMA- or GPRC5D-directed therapy, plasma cell leukemia (≥5% circulating plasma cells at the time of Talq), and penta-refractoriness were similar across groups. ECOG ≥ 2 at Talq was more common in EMD (42%), PSK (39%), EMD+ PSK (37%) than in No-STP (23%) (p = .002). Other baseline features were similar. Cytokine release syndrome (CRS) rate/severity were similar across groups. The immune effector cell–associated neurotoxicity syndrome (ICANS) was more frequent in PSK (38%) vs EMD (11%), EMD + PSK (18%), and No-STP (11%), with the most PSK cases (60%, 6/10) being grade ≥2 (p=.006). No difference in CRS/ICANS onset or duration. Infection rates were lower in No-STP (36%) vs EMD (55%), PSK (46%), and EMD+ PSK (48%) (p=.025). Best overall response rates (ORR) were 71% in EMD, 68% in PSK, 67% in EMD+PSK, and 71% in No-STP (p=.9). Complete response (CR) rates were 14% in EMD, 20% in PSK, 13% in EMD+ PSK, and 25% in No-STP (p=.1) [CRs were not required to be confirmatory, which may not meet full IMWG criteria]. Radiographic response was evaluable in 41 EMD (86%), 16 PSK (61.5%), and 48 EMD+PSK (80%) pts, with partial response (PR) or better observed in 48%, 27%, and 38%, respectively. Among pts with any STP, 34% received radiation (XRT) (4 as bridge-to-CAR T), 24 (51%) were evaluable, and 71% (n=17) achieved ≥PR. The median follow-up from Talq initiation was 10.1 months (mo) (95% CI: 8.8–11.4) and was longest in EMD (13.9 mo) compared with PSK (10.8 mo), EMD+PSK (12.4 mo), and No-STP (9.8 mo) (p = .040). Median progression-free survival (PFS) was 4.3 mo (95% CI: 3.6–5.06) in EMD, 4.8 mo (95% CI: 2.2–7.3) in PSK, 3.8 mo (95% CI: 3.1-4.5) in EMD+ PSK, and 8.3 mo (95% CI: 7.0–9.6) in No-STP (p <.001). Among pts receiving XRT for any STP (within 4 weeks prior to or during Talq), responders had longer PFS vs non-responders (15.4 vs. 2.4 mo; p=.009). Multivariable analysis (MVA) showed inferior PFS with EMD (Hazard Ratio (HR) 1.58; 95% CI, 1.04-2.3; p=.029), EMD+PSK (HR 1.91; 95% CI, 1.2–2.8; p = .001), ECOG ≥ 2 (HR 1.4; 95% CI, 1.04–1.9; p = .024), and del(17p) at any timepoint (HR 1.99; 95% CI, 1.1–3.5; p=.017), while longer time from diagnosis to Talq was modestly protective (HR 0.95 per year; p = .016), likely reflecting less aggressive biology in those reaching 5th+ line later. PSK alone showed a non-significant trend toward inferior PFS (HR 1.5; p = .1). Median overall survival (OS) was 13.0 mo (95% CI: not reached [NR]–NR) in EMD, 12.9 mo (95% CI: 6.9–18.9) in PSK, 10.9 mo (95% CI: NR–NR) in EMD+PSK, and NR (95% CI: NR–NR) in No-STP (p = .017). The primary cause of death was disease-related across all groups (p = .6). MVA for OS showed worse outcomes with EMD+PSK (HR 1.7; p=.033), ECOG ≥ 2 (HR 1.98; p <.001), and active PCL at Talq (HR 2.1; p =.010). Conclusion: Soft tissue plasmacytoma, particularly EMD and EMD+PSK, remain strong adverse prognostic factors in Talq-treated patients, with significantly shorter PFS and OS despite similar response rates. Radiation to STP sites was associated with improved outcomes in select cases. Prospective strategies are needed to optimize management for this high-risk population.
Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement
Gaballa, Mahmoud, Feng, Lei, Afrough, Aimaz, Banerjee, Rahul, Davis, James, Borogovac, Azra, Zanwar, Saurabh, Julian, Kelley, Biran, Noa, Puglianini, Omar Alexis Castaneda, Mikkilineni, Lekha, Ferreri, Christopher, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Dima, Danai, Pasvolsky, Oren, Green, Kimberly, Janakiram, Murali, Hassan, Hamza, Kalariya, Nilesh, Corraes, Andre, Fogel, Lindsay, Singhal, Ruchi, Grajales-Cruz, Ariel, Blue, Brandon, Haider, Asad, Sannareddy, Aishwarya, Seif, Sherif, Thomas, Sheeba, Rana, Masooma, Ye, J Christine, Richards, Tiffany, Hosoya, Hitomi, Atrash, Shebli, Anderson, Larry, Goldsmith, Scott, Sidana, Surbhi, Voorhees, Peter, Sborov, Douglas, Lin, Yi, Portuguese, Andrew, Hansen, Doris, Patel, Krina, Sidana, Surbhi , Hosoya, Hitomi , Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Sannareddy, Aishwarya , Gaballa, Mahmoud, Feng, Lei, Afrough, Aimaz, Banerjee, Rahul, Davis, James, Borogovac, Azra, Zanwar, Saurabh, Julian, Kelley, Biran, Noa, Puglianini, Omar Alexis Castaneda, Mikkilineni, Lekha, Ferreri, Christopher, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Dima, Danai, Pasvolsky, Oren, Green, Kimberly, Janakiram, Murali, Hassan, Hamza, Kalariya, Nilesh, Corraes, Andre, Fogel, Lindsay, Singhal, Ruchi, Grajales-Cruz, Ariel, Blue, Brandon, Haider, Asad, Seif, Sherif, Thomas, Sheeba, Rana, Masooma, Ye, J Christine, Richards, Tiffany, Atrash, Shebli, Anderson, Larry, Goldsmith, Scott, Voorhees, Peter, Sborov, Douglas, Lin, Yi, Portuguese, Andrew, Hansen, Doris, Patel, Krina

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 824-824

10.1182/blood-2025-824 Get It

Abstract Background Patients (pts) with multiple myeloma and CNS involvement (CNS MM) have poor outcomes, and we recently showed that CAR-T has activity and is reasonable in this population (Gaballa et al., 2025). We sought to evaluate the safety and efficacy of Bispecific T-cell engagers (BsAbs) in CNS MM pts, with specific interest in evaluating ICANS. Methods We conducted a retrospective study of CNS MM pts treated with BsAbs via the MM immunotherapy consortium. Primary endpoints were toxicity rates, with a specific focus on ICANS. Secondary endpoints were systemic responses, CNS responses, and survival outcomes. CNS MM was defined as involvement of the brain parenchyma, spinal cord tissue, leptomeningeal disease, or CSF positivity. CNS response was determined based on CSF and imaging, as complete CNS response, partial CNS response, and non-response/progression. Results The study included 24 pts from 13 US institutions treated with teclistamab (33%), talquetamab (50%), elranatamab (17%), and were used as monotherapy in 83% while 17% received them in combination with either daratumumab or IMiDs. The median age was 64.5 (range 41-82), 50% female, 79% white, and 17% black. High-risk cytogenetics were identified in 39%, 4% had prior primary PCL, and 21% had secondary PCL (2 active within 30 days of BsAb initiation). All pts were triple-refractory, 33% were penta-refractory, and 39% had non-CNS EMD. Pts received a median of 5 prior lines of therapy (IQR 4-7), 71% prior transplant, and 21% prior CAR-T. Prior BCMA therapy was received in 83% of the talquetamab group and 17% of the BCMA BsAbs group (teclistamab and elranatamab). CNS disease was determined based on both imaging and CSF findings in 58%, imaging only in 33%, and CSF only in 8%. Site of CNS disease included 42% brain/cranial nerves, 13% spinal cord, or 46% with both. CNS disease was diagnosed prior to BsAb in 19 pts, with a median interval of 46 days (IQR 7-234), and 3 pts were identified within 2 weeks after BsAb initiation. Two pts identified at days 68 and 121 were included in the safety evaluation but excluded from the efficacy assessments. One pt received teclistamab and intrathecal chemotherapy (IT chemo) as a bridge to CAR-T and achieved a complete CNS response before CAR-T. CNS-directed therapy consisted of: 30% radiotherapy (RT), 30% IT chemo, 13% RT + IT chemo, 9% RT + surgery, and 4% steroids. CRS grade (G) 1-2 occurred in 50%, with no G3-4 CRS. ICANS G 1, 2, and 3 occurred in 13%, 21%, and 4%, respectively, with no G 4 ICANS. One pt developed delayed parkinsonism, and another developed leukoencephalopathy; both had CNS MM diagnosed pre-BsAbs and achieved a CNS response (1 complete, 1 partial). Infections occurred in 67% of pts, with 42% being severe, and 1 infection-related death. The systemic ORR of 18 evaluable pts was 67%, including 22% CR, 17% VGPR, and 28% PR. The overall CNS response of 19 evaluable pts was 58%, including 37% complete CNS response and 21% partial CNS response. Of 11 pts achieving a CNS response, 82% didn't have subsequent CNS progression. In 9 pts achieving CNS response after BsAb initiation, the median time to CNS response was 0.9 months (range 0.03-2.8), with an unreached median duration of CNS response. With a median follow-up of 11 months, the median PFS was 5.0 months (95% CI 2.5-NA) and OS was 12.2 months (95% CI 7.7-NA). No significant difference in median PFS (10.6 vs 4.6 months, p=0.11) or OS (20.2 vs 9.3 months, p=0.37) was observed between BCMA BsAbs (n=11) and talquetamab (n=11). Due to small sample limitation, no significant difference was observed in the median PFS (4.6 vs 8.2 months, p=0.48) or OS (20.2 vs 9.9 months, p=0.73) between BsAb monotherapy (n=19) and BsAb combination therapy (n=3). One pt who received teclistamab as a bridge to CAR-T achieved a complete CNS response and remains progression-free to date, demonstrating the best long-term outcome with a PFS of 674 days. Conclusions Our study demonstrates that BsAb use in pts with CNS MM is safe without increased incidence of ICANS. The use of BsAbs in combination with a multimodal CNS-directed approach led to an overall CNS response rate of 58% and an unreached median duration of CNS response. Previous studies (Gaballa et al., 2025) reported a 100% CNS response rate with CAR-T. In this study, 1 pt treated with BsAb as a bridge to CAR-T had the longest PFS, warranting further research to evaluate this combination's efficacy in this very high-risk population.
Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)
Joiner, Laura, Pasvolsky, Oren, Afrough, Aimaz, Zanwar, Saurabh, Banerjee, Rahul, Cassano, Raffaella Cassano, Gaballa, Mahmoud, Julian, Kelley, Grajales-Cruz, Ariel, Alsina, Melissa, Goel, Utkarsh, Corraes, Andre, Dima, Danai, Rana, Masooma, Hosoya, Hitomi, Mikkilineni, Lekha, Fogel, Lindsay, Raza, Shahzad, Ali, Hossam M., Sannareddy, Aishwarya, Sborov, Douglas, Borogovac, Azra, Janakiram, Murali, Davis, James, Green, Kimberly, Biran, Noa, Hassan, Hamza, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Atrash, Shebli, Ferreri, Christopher, Midha, Shonali, Nadeem, Omar, Puglianini, Omar Alexis Castaneda, Shain, Kenneth, Abid, Muhammad Bilal, Voorhees, Peter, Khouri, Jack, Portuguese, Andrew, Lin, Yi, Sidana, Surbhi, Hansen, Doris, Patel, Krina, Costa, Luciano, Bal, Susan, Anderson, Larry, Sidana, Surbhi , Hosoya, Hitomi , Davis, James A. , Ali, Hossam M. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Ali, Hossam M , Sannareddy, Aishwarya , Joiner, Laura, Pasvolsky, Oren, Afrough, Aimaz, Zanwar, Saurabh, Banerjee, Rahul, Cassano, Raffaella Cassano, Gaballa, Mahmoud, Julian, Kelley, Grajales-Cruz, Ariel, Alsina, Melissa, Goel, Utkarsh, Corraes, Andre, Dima, Danai, Rana, Masooma, Mikkilineni, Lekha, Fogel, Lindsay, Raza, Shahzad, Ali, Hossam M., Sborov, Douglas, Borogovac, Azra, Janakiram, Murali, Davis, James, Green, Kimberly, Biran, Noa, Hassan, Hamza, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Atrash, Shebli, Ferreri, Christopher, Midha, Shonali, Nadeem, Omar, Puglianini, Omar Alexis Castaneda, Shain, Kenneth, Abid, Muhammad Bilal, Voorhees, Peter, Khouri, Jack, Portuguese, Andrew, Lin, Yi, Hansen, Doris, Patel, Krina, Costa, Luciano, Bal, Susan, Anderson, Larry

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 827-827

10.1182/blood-2025-827 Get It

Abstract Background Talquetamab (talq) is a GPRC5D-directed bispecific antibody (BsAb) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). The pivotal monumenTAL-1 clinical trial did not include patients with renal impairment (RI, creatinine clearance<40 mL/min) and therefore, data for the use of this agent in RI is lacking. Methods We examined the outcomes of patients with RRMM treated with standard of care (SOC) talq in a multicenter, retrospective cohort study. RI was defined as creatinine clearance (CrCl) <40 mL/min. For each patient we recorded demographics, disease characteristics, prior therapies, incidence and severity of adverse events of special interest, namely cytokine release syndrome (CRS) and immune-cell associated neurotoxicity syndrome (ICANS), along with response, progression-free (PFS) and overall survival (OS). We compared binary variables between different groups using Chi-squared test and assessed progression free survival (PFS) and overall survival (OS) using Kaplan Meier and Cox proportional hazards models. Patients who received talq as a bridge therapy prior to chimeric antigen receptor T-cells (CART cells) were censored for PFS analysis at the time of subsequent therapy. Results We included 417 patients who received SOC Talq and had complete datasets. 91 (22%) had RI, including 20 (5%) on dialysis. The median age was 68 and 65 years for patients with and without RI. Patients with RI were more likely to be female (64% vs. 51%), less likely to have prior CART cells (35% vs. 48%). There were no differences in performance status, race, presence of high-risk cytogenetic abnormalities [del17p, t(4;14), t(14;16), gain/amplification 1q], lines of prior therapy (median 6 vs. 6), prior ASCT (68% vs. 72%), presence of CNS disease (4% vs. 4%), prior plasma cell leukemia (8% vs 9%), prior BCMA therapy (54% vs. 61%) and triple class refractory disease (90% vs. 94%) among patients with and without RI. Rates of CRS (63% vs. 56%, P=0.21) were similar in the two groups, while severe CRS (grade ≥3: 6% vs 2%, P=0.02) was more common in patients with RI. Any grade (20% vs 14%, P=0.21) and high grade ICANS (grade ≥3: 4% vs 4%, P=0.97) were similar in patients with and without RI. There was no difference between groups on risk of infection (P=0.65) with cumulative risk at 6 months of 39% vs. 40%. With 11.1 months of median follow up, the overall response rate (60% vs 67%; P = 0.12), and progression-free survival (median 7.3 vs. 6.5 mo.; P = 0.9) were comparable between the two groups. There was no difference in outcomes according to RI in both patients previously treated with BCMA-directed therapy and BCMA-naïve. Conversely, among patients with RI, median PFS was 4.6 and 8.5 mo. for patients with and without prior BCMA therapy. Similarly, among patients without RI, median PFS was 6.5 and 6.2 mo, respectively. Among BCMA-naïve patients, there was no difference in OS between patients with and without RI (median not reached, 12 mo. OS rate 71% vs. 73%, P=0.53), while among patients with prior BCMA-directed therapy there was a trend towards better OS for patients without RI (median 8.9 vs. 13.8 mo; 12 mo. OS rate 43% vs 59%, P=0.06). Five patients (25%) became dialysis independent following talq therapy. On multivariable analysis, ECOG >1 (HR 1.62, 95% C.I. 1.25-2.10, P<0.001) and deletion of 17p (HR 1.55, 95% C.I. 1.17-2.06, P=0.003) but not RI or prior BCMA-directed therapy affected PFS. OS was affected by ECOG >1 (HR 2.37, 95% C.I 1.71-3.30, P<0.001), triple-class refractoriness (HR 3.03, 95% C.I. 1.12-8.21, P=0.03) and prior BCMA-directed therapy (HR 1.79, 95% C.I. 1.24-2.59, P=0.002) but not by RI. Conclusion Our findings support the feasibility of talq in patients with RI, including those on dialysis, with similar safety and efficacy profile to patients without RI. While neither prior BCMA-directed therapy nor RI affect PFS, refractoriness to conventional agents and prior exposure to BCMA-directed therapy adversely affects OS. This observation likely reflects better post progression survival following talq due to the availability of efficacious therapeutic options, including those directed at BCMA.
Abstract 290: Treatment Strategies for Residual and Recurrent Aneurysms After Woven EndoBridge Therapy: A Multicenter Propensity‐Matched Analysis
Gudino, Andres, Reddi, Preethi , Sridhar, V., Haranhalli, Neil , Karandish, Alireza , Aghaebrahim, Amin, Sauvageau, Eric , Crowley, W F, Dabus, Guilherme , Paul, A.R. , Puri, A, Rinaldo, Lorenzo , Brinjikji, Waleed , Goren, Oded , Siddiqui, Adnan, Jaikumar, Vinay , Essibayi, Muhammed Amir , Gutierrez‐Aguirre, Salvador F. , Hendrix, Philipp , Ransom, Ryan C. , Gudino, Andres , Ringer, Andrew J. , Kühn, Anna Luisa , Field, N., Ríos-Zermeño, Jorge , Amllay, Abdelaziz , Monteiro, Andre , Khatri, Deepak , Toledo, Otavio F. De , Crowley, W., Dabus, Guilherme C. , Matouk, Charles , Tawk, Rabih G. , Paul, A. R., Mocco, J , Majidi, Shahram , Samaniego, Edgar A , Lanzino, Giuseppe , Hanel, Ricardó A. , Altschul, David , Levy, Elad I.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_290 Get It

Introduction Post‐market and multicenter studies report low complete occlusion rates (41‐49%) and higher retreatment rates (13%) following WEB deployment, compared to 3.8% with microsurgical clipping. While retreatment after WEB has been shown to be technically feasible, data on final angiographic outcomes remain limited. We performed a retrospective analysis of prospective databases from 14 cerebrovascular centers in the US to compare the safety and efficacy of retreatment versus continued observation for residual and recurrent aneurysms after initial WEB deployment. Materials/Methods Multinomial logistic regression was used to identify baseline characteristics of untreated and residual/recurrent aneurysms that may act as confounders, which then underwent propensity scored matching (PSM). Results Among 211 patients (125 observed, 86 retreated), retreatment was more common in initially ruptured aneurysms (p<0.001), which showed higher recurrence (p=0.036) and sac‐dominant residuals (p=0.004). These were primarily due to WEB compression on follow‐up (p=0.001), rather than incomplete occlusion with an appropriately sized device (p<0.001). Retreatment was associated with significantly higher rates of complete angiographic occlusion at last follow‐up compared to observation alone (p<0.001), a finding that remained consistent across subgroups defined by initial unruptured status, residual type, and recurrence patterns (all p<0.05). Clipping demonstrated higher, though statistically insignificant, rates of complete occlusion; flow diversion and stent‐assisted coil embolization yielded comparable complete occlusion rates at follow‐up. After propensity score matching, retreatment remained significantly associated with higher rates of complete angiographic occlusion (all p<0.05), with comparable outcomes observed between clipping and various endovascular approaches as above. Conclusion Retreatment improved complete occlusion rates; however, no aneurysmal hemorrhages occurred in either group. Further intervention may be unnecessary when the WEB device—whether compressed or intact (BOSS 0/1)—adequately protects the dome. In cases where WEB compression significantly exposes the aneurysm wall, stent‐assisted coiling or flow diversion can be performed safely and successfully, depending on vascular anatomy and surgeon preference. image image
Impact of RAS / BRAF V600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair–Deficient/Microsatellite Instability Colorectal Cancers
Salem, Mohamed E. , Puccini, Alberto , Mauer, Elizabeth , André, Thierry , George, Thomas J. , Tabernero, Josep , Sinicrope, Frank A. , Kopetz, Scott , Cutsem, Eric Van , Overman, Michael J. , Foureau, David , Tie, Jeanne , Kopetz, Scott , Van Cutsem, Eric , Lonardi, Sara , Overman, Michael J , Foureau, David , Mauer, Elizabeth , Sinicrope, Frank A , George, Thomas J , André, Thierry , Tabernero, Josep , Tie, Jeanne , Lonardi, Sara

Mayo Clinic

Clinical Cancer Research | November 14, 2025 | Volume: 32 | Issue: 2 | Pages: 417-427

10.1158/1078-0432.ccr-25-2160 | PMID 41235954 Get It

Abstract Purpose: Routine testing for mismatch repair deficiency (dMMR)/microsatellite instability (MSI) in colorectal cancers is recommended for Lynch syndrome screening, prognosis, and treatment guidance. In the metastatic setting, RAS/BRAF mutations guide treatment decisions. The impact of these mutations on the tumor immune microenvironment (TiME) in MSI/dMMR colorectal cancer is not known. Experimental Design: The study involved retrospective analysis of 448 patients with stage I to IV MSI/dMMR colorectal cancer profiled using next-generation sequencing (Tempus xT DNA sequencing of 595–648 genes at 500x coverage and Tempus xR whole-exome capture RNA sequencing). MSI status was determined by assessing 44 or 239 loci using next-generation sequencing. dMMR was determined using IHC. Tumor mutational burden, tumor neoantigen burden (NTB), PD-L1, immune infiltration, and canonical immune pathways (76 gene set signatures) were analyzed. Results: The median age at diagnosis was 67 years (range, 21–86); 59% of patients were female, and 70% were stage III to IV. Among the 448 patients, 100 (22%) harbored RAS mutations (RASmut), 119 (27%) a BRAFV600E mutation, and 229 (51%) were double wild type. RASmut exhibited lower NTB (median, 12 vs. 15 vs. 16; P = 0.003) and PD-L1 (3.6% vs. 13% vs. 24%; P &lt; 0.001) than BRAFV600E and wild-type tumors, respectively. The RASmut TiME had lower overall inflammation and fewer infiltrating CD8+ T cells than wild-type or BRAFV600E tumors. In contrast, BRAFV600E tumors exhibited hyperproliferative characteristics associated with broad metabolic reprogramming but a similarly inflamed TiME compared with wild-type tumors. Conclusions: Our data suggest that MSI/dMMR colorectal cancers harboring RASmut are less immunogenic, and the TiME contains a lower inflammatory profile than wild-type or BRAFV600E tumors. Further analysis and validation are required to confirm these findings.
NCOG-27. Neuro-oncology anywhere: A fully decentralized clinical trial evaluating cognitive assessments and interventions for patients who received intracranial radiation therapy
Neth, Bryan J. , Galloway, Taylor , Hughes, Heather , Caron, Samantha, Batty, N., Alden, Eva , Kizilbash, Sani H. , Breen, William G. , Lehrer, Eric J. , Campian, Jian , Uhm, Joon H. , Ruff, Michael W. , Burns, Stacy D’Andre Terry, Haddad, Tufia C. , Flickinger, Lynn M. , Chan, Katrina, Mead‐Harvey, Carolyn , Geyer, Susan, Chan, Katrina , Neth, Byran J. , Kizilbash, Sani H , Sener, Uğur , Stricker, Nikki H. , Burns, Stacy D’Andre Terry

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v327-v327

10.1093/neuonc/noaf201.1294 Get It

Abstract BACKGROUND Cognitive symptoms are common among cancer patients treated with intracranial radiation but inadequately assessed and suboptimally treated, owing in part to the time-consuming and resource-intensive nature of formal neuropsychological testing. Through remote administration of brief cognitive assessments and symptom-directed interventions, decentralization uniquely addresses this problem. METHODS In this single-site phase 2 fully decentralized clinical trial (NCT06377696), patients treated with radiation therapy (RT) for primary or metastatic brain tumors undergo cognitive evaluations with the application, Mayo Test Drive, and the Short Test of Mental Status (STMS; via telehealth or in person), at baseline and every three months for one year. Participants are provided wearable devices for health promotion. Half the participants are randomized to metformin to evaluate this agent’s efficacy in treating RT-related cognitive symptoms. Target enrollment is 100 participants. RESULTS Seventy-three patients (median age 45.5, 46% female) with brain tumors who received RT were enrolled May 2024 to May 2025. In this unplanned interim analysis, we evaluated the impact of decentralization on study participation. Thirty-six participants (49%) reported a primary residence greater than 150 miles from our institution. Seven patients were consented remotely, the remainder in person. Of 380 study-related visits (201 STMS, 179 treatment toxicity checks) 216 (57%) were completed by telehealth. Thirty-two of 336 (9.5%) study-related lab draws were completed at locations outside our institution. Wearable device data was continuously collected, with median 3022 steps tracked per patient per day on study. 190/250 (76%) quality-of-life surveys sent digitally were completed to date. CONCLUSION Decentralization implemented as part of this clinical trial enabled participation despite significant distance from our institution and facilitated study-related assessments through digital solutions, eliminating the need for travel. Our findings demonstrate the feasibility of conducting a fully decentralized supportive care trial in neuro-oncology, which can increase participation and accelerate evaluation of novel therapeutics.
844 Immune cell profile changes in patients treated with tarlatamab for extensive-stage small cell lung cancer in real world practice
Ma, Audrey, Corraes, Andre De Menezes Silva , Wu, Chen , Shao, Zuoyi , Regan, Kevin M., Karam, Dhauna , Potter, Ashley , Al‐Ajmi, Abdullah, Mina, Syeda A. , Taylor, Skyler, Parikh, Kaushal , Shanshal, Mohamed , Luce, A., Schwecke, Anna, Lin, Yi , Leventakos, Konstantinos , Taylor, Skyler J, Hazim, Antonious , Dimou, Anastasios , Molina, Julian, Mansfield, Aaron S. , Smith, Katherine E.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A953-A954

10.1136/jitc-2025-sitc2025.0844 Get It

281 T cell metabolic pathway enrichment profiles associated with clinical response in CD19 CAR-T therapy for aggressive B-cell non-Hodgkin’s lymphoma
Tan, Melinda Si Yun , Wang, Panwen , Corraes, Andre De Menezes Silva , Wu, Chen , Shao, Zuoyi , Regan, Kevin M., Ma, Audrey, Khurana, Arushi , Bennani, Nabila N, Hampel, Paul J. , Johnston, Patrick B. , Ansell, Stephen M. , Bennani, Nabila N, Wang, Yucai , Paludo, Jonas , Durani, Urshila , Villasboas, José C. , Mondello, Patrizia , Zeng, Hu , Dong, Haidong , Li, Ying , Lin, Yi

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A314-A314

10.1136/jitc-2025-sitc2025.0281 Get It